Development of an ultrasensitive assay for human prion proteins. The aim of this work is to enable the detection of prion proteins in human blood and other tissues. The assay system to be developed will detect much lower levels of these disease-causing proteins than is possible at present; it will be more rapid and will measure prion protein levels more accurately than existing assays. The outcome of the work is expected to facilitate the production and certification of prion-free blood and bl ....Development of an ultrasensitive assay for human prion proteins. The aim of this work is to enable the detection of prion proteins in human blood and other tissues. The assay system to be developed will detect much lower levels of these disease-causing proteins than is possible at present; it will be more rapid and will measure prion protein levels more accurately than existing assays. The outcome of the work is expected to facilitate the production and certification of prion-free blood and blood products. Prions cause Bovine Spongiform Encaphalopathy and Creutzfeld Jacob Disease and attempts to control of these diseases would be greatly abetted by an optimal test for the disease-causing agent.Read moreRead less
Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management ....Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management of those at risk of heart attack, the single biggest contributor to healthcare costs in Australia. We further aim to adapt this technology to enable "point-of-care" assays that would help medical practitioners, especially in rural areas, to make informed diagnoses immediately.Read moreRead less